Eikon Therapeutics, Inc. (EIKN)
NASDAQ: EIKN · Real-Time Price · USD
9.66
-1.05 (-9.77%)
At close: Apr 24, 2026, 4:00 PM EDT
9.40
-0.25 (-2.64%)
After-hours: Apr 24, 2026, 7:30 PM EDT

Eikon Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023
Period Ending
Dec '25 Dec '24 Dec '23
Selling, General & Admin
88.6355.8158.48
Research & Development
250.32204.54207.26
Total Operating Expenses
338.95260.34265.74
Operating Income
-338.95-260.34-265.74
Interest Income
15.5716.5623.74
Interest Expense
-0.84-0.03-0.04
Other Non-Operating Income (Expense)
-0.03-00.04
Total Non-Operating Income (Expense)
14.716.5323.74
Pretax Income
-324.25-243.81-242
Net Income
-333.64-243.81-242
Net Income Attributable to Preferred Dividends
9.4--
Net Income to Common
-333.64-243.81-242
Shares Outstanding (Basic)
332
Shares Outstanding (Diluted)
332
Shares Change (YoY)
14.85%24.32%-
EPS (Basic)
-115.29-96.76-119.40
EPS (Diluted)
-115.29-96.76-119.40
Shares Outstanding
3.072.872.83
Free Cash Flow
-235.26-219.6-219.36
Free Cash Flow Per Share
-81.29-87.16-108.23
EBITDA
-320.07-245.34-254.31
EBIT
-338.95-260.34-265.74
Updated Jan 9, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q